Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Clinical trial NCT06056336 · RECRUITING

Trial details

NCT number: NCT06056336
Sponsor: Guo Xufeng
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma Neoadjuvant Chemoimmunotherapy Adjuvant Therapy

Start date: 2023-09-07
Primary completion: 2024-09-30
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.